chevron-down Created with Sketch Beta.
May 19, 2023

Phase 1 Trial Shows Promising Use of Vaccines in Patients with Pancreatic Cancer

On May 10, 2023, researchers from Memorial Sloan Kettering Cancer Center published results from a phase 1 clinical trial of the use of Messenger RNA vaccines (used to prevent or lessen the impact of COVID-19 infection) in treating patients with pancreatic cancer following resection of their tumors.  Post-surgical treatment that included the vaccines triggered a robust immune response that delayed the recurrence of patients’ pancreatic cancer.  The next steps include conducting a much larger and randomized clinical trial across multiple locations beginning summer 2023.

The material in all ABA publications is copyrighted and may be reprinted by permission only. Request reprint permission here.